Newsroom

Company updates and notices

Announcements from Ergopharm — company updates, quality and serialisation notices, and product register changes.

Newsroom2005 → 2026

Press · Regulatory · Company40+ updates

2026

2026 · 06Register

Product register expanded to twenty-seven monographs

The export portfolio now spans sterile injectable ampoules and oral solids, each with a serialised monograph.

2026 · 04Serialisation

GS1 DataMatrix applied across all cartons

Every pack now leaves the line with a unique serial and human-readable data line, verifiable online.

2026 · 01Company

Twenty years of manufacturing in Vadodara

The company marks two decades from analytical laboratory to serialised export manufacturer.

2025

2025 · 09Register

Post-cycle therapy range added to the register

Tamoxifen and clomiphene monographs join the oral-solid portfolio.

2025 · 08Medical

Medical information service opened for healthcare professionals

Prescribers and pharmacists can put clinical questions about the products directly to the company.

2025 · 03Export

Distribution reaches forty markets

Licensed partners in more than forty markets now carry the register.

2024

2024 · 05Capacity

Second oral-solid packaging line commissioned

Additional blister and bulk capacity added to meet export demand.

2024 · 04Partners

Documentation portal opened for distributors

Partners can retrieve current specifications, certificates and pack details from a single controlled source.

2023

2023 · 11Register

Register restructured into ampoules and tablets

The catalogue is reorganised around dosage form, with a single documentation template per monograph.

2023 · 02Digital

Online pack verification portal launched

Distributors and patients can confirm a carton from the code printed on its serialisation panel.

2022

2022 · 11Capacity

Annual ampoule output passes one hundred million

Sterile output crosses nine figures as both filling lines run at qualified capacity.

2021

2021 · 09Export

European distribution partnerships expanded

Additional European partners are onboarded, each with market-specific labelling and data exchange.

2021 · 06Register

Boldenone and trenbolone monographs added

The injectable range expands to six esters.

2020

2020 · 09Company

Site headcount passes six hundred

Manufacturing, quality and engineering teams grow as the second sterile line reaches full output.

2020 · 03Export

Cold-chain export lanes qualified

Temperature-controlled lanes validated for international distribution under GDP.

2019

2019 · 05Register

Oral portfolio broadened across therapeutic classes

The tablet register grows beyond a single class, adding agents with quite different pharmacology.

2019 · 02Compliance

Safety features live across the portfolio

A unique identifier and anti-tampering device are applied to every outer carton.

2018

2018 · 11Capacity

Blister packaging line commissioned for oral solids

Tablets move from bulk to unit-dose blister packs with in-line seal integrity checking.

2018 · 02Serialisation

Serialisation and aggregation line commissioned

GS1 DataMatrix printing, in-line vision verification and case aggregation added at the end of the line.

2017

2017 · 10Facility

Oral-solid-dose facility opened

Granulation, compression and coating brought in-house.

2017 · 08Facility

Tablet compression and coating equipment commissioned

Granulation, compression and coating equipment is installed and qualified ahead of the oral-solid facility opening.

2017 · 06Capacity

Ampoule filling capacity increased

A second filling line lifts sterile output and provides redundancy for the first.

2016

2016 · 05Export

Distribution network passes twenty markets

Licensed distributors in more than twenty markets now carry Ergopharm products.

2015

2015 · 05Export

First export distribution agreements signed

Ergopharm begins supplying licensed distributors across export markets.

2015 · 02Register

Injectable portfolio reaches double figures

The tenth sterile monograph enters the register as the ampoule line settles into routine supply.

2014

2014 · 01Register

Ampoule range extended to four esters

Additional injectable monographs join the register following stability and process validation.

2013

2013 · 03Export

First sterile export consignment dispatched

Aseptically filled ampoules leave the site for a licensed distributor for the first time.

2012

2012 · 09Facility

Sterile fill–finish line qualified

Aseptic ampoule filling under Grade A / B commissioned and qualified.

2012 · 03Facility

Sterile block construction completed

The aseptic filling block is handed over for qualification ahead of the first media fills.

2011

2011 · 03Facility

Sterile block construction begins

Work starts on a dedicated aseptic facility with its own airlocks, utilities and personnel routes.

2010

2010 · 10Development

Pilot-scale suite commissioned for development batches

A dedicated suite lets new products be made at intermediate scale before commercial equipment is committed.

2010 · 08Development

Oral solid-dose development work begins

A formulation group is set up to develop tablet products alongside the existing injectable range.

2009

2009 · 06Export

Export documentation function established

A dedicated team is set up to compile the technical documentation partners need for their own filings.

2009 · 04Quality

Quality control laboratory established

In-house analytical testing introduced for identity, assay and stability.

2008

2008 · 10Export

First export consignment dispatched

The company ships its first consignment to a licensed importer, under a written quality agreement.

2007

2007 · 09Facility

Warehouse and controlled-temperature storage commissioned

Mapped storage areas with quarantine, released and rejected segregation come into use.

2007 · 02Company

First commercial batch released

The inaugural oral-solid batch is released against its finished-product specification.

2006

2006 · 09Development

Formulation development begins on injectable esters

Laboratory work starts on oil-carrier injectable formulations and their analytical methods.

2006 · 04Facility

Construction begins on the first manufacturing block

Ground is broken on the oral-solid-dose block that will take the company from testing into manufacture.

2005

2005 · 10Company

Founding technical team recruited

Analytical chemists, microbiologists and engineers join ahead of the first manufacturing block.

2005 · 06Company

Ergopharm Advanced Research Centre founded

The company is established in Vadodara, Gujarat, to manufacture prescription medicines for export.

Product register expanded to twenty-seven monographs→

GS1 DataMatrix applied across all cartons→

Twenty years of manufacturing in Vadodara→

Post-cycle therapy range added to the register→

Medical information service opened for healthcare professionals→

Distribution reaches forty markets→

Second oral-solid packaging line commissioned→

Documentation portal opened for distributors→

Register restructured into ampoules and tablets→

Online pack verification portal launched→

Annual ampoule output passes one hundred million→

European distribution partnerships expanded→

Boldenone and trenbolone monographs added→

Site headcount passes six hundred→

Cold-chain export lanes qualified→

Oral portfolio broadened across therapeutic classes→

Safety features live across the portfolio→

Blister packaging line commissioned for oral solids→

Serialisation and aggregation line commissioned→

Oral-solid-dose facility opened→

Tablet compression and coating equipment commissioned→

Ampoule filling capacity increased→

Distribution network passes twenty markets→

First export distribution agreements signed→

Injectable portfolio reaches double figures→

Ampoule range extended to four esters→

First sterile export consignment dispatched→

Sterile fill–finish line qualified→

Sterile block construction completed→

Sterile block construction begins→

Pilot-scale suite commissioned for development batches→

Oral solid-dose development work begins→

Export documentation function established→

Quality control laboratory established→

First export consignment dispatched→

Warehouse and controlled-temperature storage commissioned→

First commercial batch released→

Formulation development begins on injectable esters→

Construction begins on the first manufacturing block→

Founding technical team recruited→

Ergopharm Advanced Research Centre founded→